Search research articles
Contact Us
Filters
Showing results (141-150 of 162) with videos related to
Page
of 17
Sort By:
Kidney International
|
December 14, 2020
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice
Megumi Oshima, Meg J Jardine, Rajiv Agarwal, et al.
Journal of Diabetes Research
|
June 9, 2022
Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial
Tamara K Young, Nigel D Toussaint, Gian Luca Di Tanna, et al.
Journal of the American College of Cardiology
|
September 1, 2024
Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 Diabetes
Brendon L Neuen, John W Ostrominski, Brian Claggett, et al.
Diabetes, Obesity & Metabolism
|
May 10, 2023
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials
Amy Kang, Brendan Smyth, Brendon L Neuen, et al.
BMJ Open Diabetes Research & Care
|
June 13, 2023
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
David M Charytan, Kenneth W Mahaffey, Meg J Jardine, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
November 20, 2020
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m<sup>2</sup>: Subgroup Analysis of the Randomized CREDENCE Trial
George Bakris, Megumi Oshima, Kenneth W Mahaffey, et al.
Journal of the American Heart Association
|
August 5, 2022
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial
Jing-Wei Li, Clare Arnott, Hiddo J L Heerspink, et al.
American Journal of Nephrology
|
December 19, 2017
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics
Meg J Jardine, Kenneth W Mahaffey, Bruce Neal, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
March 8, 2023
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial
Tae Won Yi, Brendan Smyth, Gian Luca Di Tanna, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
February 25, 2018
Scope and Consistency of Outcomes Reported in Randomized Trials Conducted in Adults Receiving Hemodialysis: A Systematic Review
Bénédicte Sautenet, Allison Tong, Gabrielle Williams, et al.
Page
of 17
Search research articles
Search
Showing results (141-150 of 162) with videos related to
Sort By:
Page
of 17
Kidney International
|
December 14, 2020
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice
Megumi Oshima, Meg J Jardine, Rajiv Agarwal, et al.
Journal of Diabetes Research
|
June 9, 2022
Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial
Tamara K Young, Nigel D Toussaint, Gian Luca Di Tanna, et al.
Journal of the American College of Cardiology
|
September 1, 2024
Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 Diabetes
Brendon L Neuen, John W Ostrominski, Brian Claggett, et al.
Diabetes, Obesity & Metabolism
|
May 10, 2023
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials
Amy Kang, Brendan Smyth, Brendon L Neuen, et al.
BMJ Open Diabetes Research & Care
|
June 13, 2023
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
David M Charytan, Kenneth W Mahaffey, Meg J Jardine, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
November 20, 2020
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m<sup>2</sup>: Subgroup Analysis of the Randomized CREDENCE Trial
George Bakris, Megumi Oshima, Kenneth W Mahaffey, et al.
Journal of the American Heart Association
|
August 5, 2022
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial
Jing-Wei Li, Clare Arnott, Hiddo J L Heerspink, et al.
American Journal of Nephrology
|
December 19, 2017
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics
Meg J Jardine, Kenneth W Mahaffey, Bruce Neal, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
March 8, 2023
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial
Tae Won Yi, Brendan Smyth, Gian Luca Di Tanna, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
February 25, 2018
Scope and Consistency of Outcomes Reported in Randomized Trials Conducted in Adults Receiving Hemodialysis: A Systematic Review
Bénédicte Sautenet, Allison Tong, Gabrielle Williams, et al.
Page
of 17